Dr. Winter on the Promise of CAR T-Cell Therapy in Hematologic Malignancies

Jane N. Winter, MD
Published: Tuesday, Oct 10, 2017



Jane N. Winter, MD, professor of medicine, Division of Hematology/Oncology, Northwestern University, discusses the promise of chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies.

It is too early to determine benefit of CAR T-cell therapy in follicular lymphoma, says Winter, with responses ranging from 40% to 50%. Although, there may be promise in combining other agents or altering the technique.

A large benefit has been seen in other hematologic malignancies such as diffuse large B-cell lymphoma, states Winter.
 
SELECTED
LANGUAGE


Jane N. Winter, MD, professor of medicine, Division of Hematology/Oncology, Northwestern University, discusses the promise of chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies.

It is too early to determine benefit of CAR T-cell therapy in follicular lymphoma, says Winter, with responses ranging from 40% to 50%. Although, there may be promise in combining other agents or altering the technique.

A large benefit has been seen in other hematologic malignancies such as diffuse large B-cell lymphoma, states Winter.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x